Although biotech stocks, along with the general markets, performed poorly last quarter, more companies were able to access capital, more than in each of the previous four quarters. Excluding US partnership monies, 219 companies pulled in $8.1 billion (compared with 157 firms raising $5.3 billion in 2Q09), 39% of which originated from debt deals by Genzyme (Cambridge, MA) and Teva Pharmaceuticals (Petah Tikva, Israel). Venture funding was up 36% from 2Q09; ten companies launched initial public offerings (IPOs), raising $342.9 million.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. 2Q10—spreading the wealth. Nat Biotechnol 28, 771 (2010). https://doi.org/10.1038/nbt0810-771
Issue Date:
DOI: https://doi.org/10.1038/nbt0810-771
